The list of peptides for muscle growth is shorter than the supplement aisle suggests. Nearly all of it comes from one hormone pathway, and the trials behind it were run to treat illness.
Ranked by evidence rather than reputation, the growth-hormone peptides line up like this: tesamorelin is FDA-approved with real trials, but for the wrong indication. CJC-1295 and ipamorelin have coherent mechanisms and thin human data, while sermorelin has 1990s trials and was discontinued as a drug. IGF-1 LR3 acts directly and has the least safety data. Almost none of them were studied for muscle growth in healthy adults.
Nearly every “best peptides for muscle growth” list ranks by how often a compound is mentioned. This one ranks by what was actually measured, which produces a different and less exciting order — and one important framing note up front: raising growth hormone is a biochemical outcome, building muscle is a clinical one, and the literature is much stronger on the first than the second.
The ranking, by evidence
| Compound | Mechanism | Human evidence | The catch |
|---|---|---|---|
| Tesamorelin | Stabilized GHRH analog | Strongest here — FDA-approved as Egrifta | Approved for HIV lipodystrophy, not hypertrophy |
| CJC-1295 | GHRH analog; bigger GH pulses | Mechanistic, limited outcome data | DAC and no-DAC forms behave very differently |
| Ipamorelin | Selective GHS-R agonist; more frequent pulses | Mechanistic, limited outcome data | Selectivity is the selling point, not potency |
| Sermorelin | GHRH(1-29), the original fragment | 1990s trials restored IGF-1 to young-adult range | Discontinued as a drug; no modern RCTs |
| IGF-1 LR3 | Acts directly on muscle, bypassing the GH axis | Weakest human safety data of the group | Direct mitogenic action is exactly why that matters |
| Hexarelin | Most potent GH secretagogue of the class | Limited | Desensitizes fastest |
Why the GH axis dominates this list
Growth hormone drives IGF-1 production in the liver, and IGF-1 is the anabolic signal that actually reaches muscle. Rather than administering GH directly, secretagogues push the body's own pulsatile release — which is the argument for them, since pulsatility is how the axis normally works and a continuous signal desensitizes it.
Two receptor routes exist and they are complementary rather than redundant. GHRH analogs (sermorelin, CJC-1295, tesamorelin) increase pulse amplitude. Ghrelin-receptor agonists (ipamorelin, hexarelin) increase pulse frequency and suppress somatostatin. That non-overlap is the entire rationale for the CJC-1295 / ipamorelin stack, and the GH axis overview covers the pharmacology properly.
The gap this list cannot close. Sermorelin's 1990s trials restored IGF-1 to the young-adult range in about two weeks. That is a real, measured, replicated biochemical effect. What no trial in this group established is that the same intervention produces meaningful lean-mass gain in a healthy, trained adult who is already eating and lifting adequately. The mechanism is sound; the outcome study mostly does not exist. What the sermorelin trials actually showed is the clearest illustration.
The repair compounds, and why they're on stacks
BPC-157 and TB-500 turn up in almost every muscle-focused stack, and they are not anabolic. The preclinical work is on tendon, ligament, muscle and gut healing. Their place in a training context is that injuries stop training, and training is what builds muscle — an indirect route, and a legitimate one, but a different claim from hypertrophy. See BPC-157 vs TB-500 and the Wolverine stack.
CJC-1295 / Ipamorelin blend
The two-mechanism GH-axis combination discussed above, in a single vial. Research use only — supplied with a batch-matched certificate of analysis.
If you are buying any of these
The GH-axis compounds are among the most frequently underfilled and substituted in the market, for a specific reason: they are dosed in micrograms, sold in small vials, and produce effects too subtle for a buyer to notice a shortfall. Nobody detects a 30% underfill of ipamorelin by feel.
That makes analytical verification the whole game here. A batch-matched certificate of analysis showing both HPLC purity and mass-spec identity is the floor — how to read one — and cost per mg is the only fair way to compare across the vial sizes these are sold in. Per-compound sourcing guides: ipamorelin, CJC-1295, tesamorelin.
Frequently asked questions
What are the best peptides for muscle growth?
The honest ranking is by evidence quality, not by reputation. Tesamorelin has the strongest data because it is FDA-approved as Egrifta with real trials behind it, though for HIV-associated lipodystrophy rather than muscle building. CJC-1295 and ipamorelin have coherent mechanisms and thin human evidence. IGF-1 LR3 acts directly on muscle and has the least human safety data of the group.
Do growth hormone peptides actually build muscle?
They raise growth hormone and IGF-1, which is not the same claim. Restoring an IGF-1 level to the young-adult range is a measurable biochemical change; producing meaningful hypertrophy in a healthy trained adult is a clinical outcome, and almost no trial in this space measured the second one.
What is the difference between CJC-1295 and ipamorelin?
They act on different receptors and are usually discussed together for that reason. CJC-1295 is a GHRH analog that increases the size of GH pulses; ipamorelin is a selective ghrelin-receptor agonist that increases their frequency. The rationale for stacking them is complementary mechanism, not additive dosing.
Is BPC-157 a muscle-building peptide?
No. BPC-157 is a tissue-repair compound — the preclinical work is on tendon, muscle, ligament and gut healing, not hypertrophy. It appears in muscle-focused stacks because training injuries interrupt training, which is a different mechanism of benefit entirely.
CJC-1295 / Ipamorelin blend
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Tesamorelin is the only FDA-approved compound here, and its approval is for a different indication entirely.
- CJC-1295 and ipamorelin have coherent mechanisms but thin human data behind them.
- Sermorelin has trials from the 1990s and was later discontinued as a drug.
- IGF-1 LR3 acts directly and carries the least safety data of the compounds on this list.
- Almost none of these were studied for muscle growth in healthy adults, which is the gap everything else sits on.
References
- Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
- Sigalos, J. T., & Pastuszak, A. W. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004
- Falutz, J., Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/qad.0b013e32830a5058
- Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4). https://doi.org/10.1177/15563316251355551
Tesamorelin's evidence is from its HIV-lipodystrophy programme, which is the indication it is approved for — not hypertrophy.